Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma

References

• El–Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576. doi:10.1053/j.gastro.2007.04.061
   PubMed Web of Science ®Google Scholar
• Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Current concepts hepatocellular carcinoma. N Eng J Med. 2011;365(12):1118–1127. doi:10.1056/NEJMra1001683
   PubMed Web of Science ®Google Scholar
• Brady CW, Smith AD, Stechuchak KM, et al. Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. Liver Transplantation. 2008;14(2):228–234. doi:10.1002/lt.21346
   PubMed Web of Science ®Google Scholar
• Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology. 2014;59(6):2188–2195. doi:10.1002/hep.26986
   PubMed Web of Science ®Google Scholar
• Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–428.
   PubMed Web of Science ®Google Scholar
• Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging. 2014;39(5):1070–1087. doi:10.1007/s00261-014-0130-0
   PubMedGoogle Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Nat Comprehensive Cancer Network. 2021;19(5):541–565. doi:10.6004/jnccn.2021.0022
   PubMedGoogle Scholar
• Koh JH, Tan DJH, Ong Y, et al. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobil Surg Nutr. 2021;21.
   Web of Science ®Google Scholar
• Galle PR, Dufour J-F, Peck-Radosavljevic M, Trojan J, Vogel A. Systemic therapy of advanced hepatocellular carcinoma. Future Oncol. 2021;17(10):1237–1251. doi:10.2217/fon-2020-0758
   PubMed Web of Science ®Google Scholar
• Giannini EG, Farinati F, Ciccarese F, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184–190. doi:10.1002/hep.27443
   PubMed Web of Science ®Google Scholar
• Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62(6):1420–1429. doi:10.1016/j.jhep.2015.02.038
   PubMed Web of Science ®Google Scholar
• Xu D, Fu J, Jin L, et al. Circulating and liver resident CD4+ CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol. 2006;177(1):739–747. doi:10.4049/jimmunol.177.1.739
   PubMed Web of Science ®Google Scholar
• Knoll P, Schlaak J, Uhrig A, Kempf P, Zum Büschenfelde K-HM, Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol. 1995;22(2):226–229. doi:10.1016/0168-8278(95)80433-1
   PubMed Web of Science ®Google Scholar
• Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007;46(1):48–57. doi:10.1002/hep.21672
   PubMed Web of Science ®Google Scholar
• Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: patho-physiological mechanisms and therapeutic perspectives. Eur J Cancer. 2017;87:101–112. doi:10.1016/j.ejca.2017.10.010
   PubMed Web of Science ®Google Scholar
• El Dika I, Khalil DN, Abou‐Alfa GK. Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer. 2019;125(19):3312–3319. doi:10.1002/cncr.32076
   PubMed Web of Science ®Google Scholar
• Wong KM, King GG, Harris WP. The treatment landscape of advanced hepatocellular carcinoma. Curr Oncol Rep. 2022;24(7):917–927. doi:10.1007/s11912-022-01247-7
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Eng J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Kim BK, Cheon J, Kim H, et al. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: a Real-World, Multi-Center Study. Cancers. 2022;14(7):1747. doi:10.3390/cancers14071747
   PubMed Web of Science ®Google Scholar
• Chao J, Zhu Q, Chen D, et al. Case Report: transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection. Front Oncol. 2021;11:667555. doi:10.3389/fonc.2021.667555
   PubMed Web of Science ®Google Scholar
• Takamoto T, Maruki Y, Kondo S. Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma. Expert Opin Pharmacother. 2023;1–9.
   Web of Science ®Google Scholar
• Gao Q, Anwar IJ, Abraham N, Barbas AS. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers. 2021;13(24):6307. doi:10.3390/cancers13246307
   PubMed Web of Science ®Google Scholar
• Mousa AB. Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi j Gastroenterol. 2008;14(1):40. doi:10.4103/1319-3767.37808
   PubMedGoogle Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Eng j Medicine. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Berk V, Kaplan M, Tonyali O, et al. Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the Anatolian Society of Medical Oncology. Asian Pacific J Cancer Prevention. 2013;14(12):7367–7369. doi:10.7314/APJCP.2013.14.12.7367
   PubMedGoogle Scholar
• Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta‐analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011;36(4):344–350. doi:10.1111/j.1365-2230.2011.04060.x
   PubMed Web of Science ®Google Scholar
• Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician’s perspective. Semin Oncol. 2014;41:S1–S16. doi:10.1053/j.seminoncol.2014.01.001
   PubMedGoogle Scholar
• Dai C, Zhou F, Shao J-H, Wu L-Q, Yu X, Yin X-B. Bleeding risk in cancer patients treated with sorafenib: a meta-analysis of randomized controlled trials. J Cancer Res Ther. 2018;14(Suppl 5):S948–S956. doi:10.4103/0973-1482.188430
   PubMedGoogle Scholar
• Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a review in hepatocellular carcinoma. Drugs. 2019;79:665–674. doi:10.1007/s40265-019-01116-x
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. Cabozantinib: an evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021;98:102221. doi:10.1016/j.ctrv.2021.102221
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Eng J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. Cancer J. 2018;24(4):193–204. doi:10.1097/PPO.0000000000000327
   PubMed Web of Science ®Google Scholar
• Morse MA, Sun W, Kim R, et al. The Role of Angiogenesis in Hepatocellular CarcinomaRole of Angiogenesis in HCC. Clin Cancer Res. 2019;25(3):912–920. doi:10.1158/1078-0432.CCR-18-1254
   PubMed Web of Science ®Google Scholar
• Boige V, Malka D, Bourredjem A, et al. Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2012;17(8):1063–1072. doi:10.1634/theoncologist.2011-0465
   PubMed Web of Science ®Google Scholar
• Fang P, Hu J-H, Cheng Z-G, Liu Z-F, Wang J-L, Jiao S-C. Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: a Systematic Review of Phase II Trials. PLoS One. 2012;7(12):e49717. doi:10.1371/journal.pone.0049717
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Yau T, Kang Y-K, Kim T-Y, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: the CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020;6(11):e204564–e204564. doi:10.1001/jamaoncol.2020.4564
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. Journal of Clinical Oncology. 2020;38(3):193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Finn R, Kudo M, Merle P, et al. LBA34 Primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022;33:S1401. doi:10.1016/j.annonc.2022.08.031
   Web of Science ®Google Scholar
• Llovet JM, Vogel A, Madoff DC, et al. Randomized Phase 3 LEAP-012 Study: transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. Cardiovasc Intervent Radiol. 2022;45(4):405–412. doi:10.1007/s00270-021-03031-9
   PubMed Web of Science ®Google Scholar
• Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. Am Soc Clin Oncol. 2017;35(15_suppl):4073. doi:10.1200/JCO.2017.35.15_suppl.4073
   Web of Science ®Google Scholar
• Kelley RK, Sangro B, Harris W, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021;39(27):2991–3001. doi:10.1200/JCO.20.03555
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379. doi:10.1200/JCO.2022.40.4_suppl.379
   Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDoa2100070
   PubMedGoogle Scholar
• Gu T, Jiang A, Zhou C, et al. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis. Int J Cancer. 2023;152(3):480–495. doi:10.1002/ijc.34332
   PubMed Web of Science ®Google Scholar
• Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol. 2021;13:17588359211031141. doi:10.1177/17588359211031141
   Web of Science ®Google Scholar
• Kanbayashi Y, Ishikawa T, Tabuchi Y, et al. Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis. Sci Rep. 2020;10(1):2011. doi:10.1038/s41598-020-58994-5
   PubMed Web of Science ®Google Scholar
• Ogasawara S, Koroki K, Makishima H, et al. Protocol: durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open. 2022;12(4):e059779. doi:10.1136/bmjopen-2021-059779
   PubMed Web of Science ®Google Scholar
• Table of Pharmacogenomic Biomarkers in Drug Labeling. US Food & Drug Administration. Updated August 10, 2023. Available from: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. Accessed August 25, 2023.
   Google Scholar
• Abou-Alfa GK, Fan J, Heo J, et al. 727TiP A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3. Ann Oncol. 2022;33:S874.
   Web of Science ®Google Scholar
• Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–551. doi:10.1016/j.jhep.2016.10.029
   PubMed Web of Science ®Google Scholar
• Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: a review. World J Gastroenterol. 2021;27(32):5376–5391. doi:10.3748/wjg.v27.i32.5376
   PubMed Web of Science ®Google Scholar
• Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018;38(6):976–987. doi:10.1111/liv.13746
   PubMed Web of Science ®Google Scholar
• Health UDo, Services H. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. 2017; 2023.
   Google Scholar
• Food, Administration D. Drug-induced liver injury: premarketing clinical evaluation. Guidance Industry. 2009.
   Google Scholar
• Palmieri DJ, Carlino MS. Immune Checkpoint Inhibitor Toxicity. Curr Oncol Rep. 2018;20(9):72. doi:10.1007/s11912-018-0718-6
   PubMed Web of Science ®Google Scholar
• Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406–417. doi:10.1111/apt.13281
   PubMed Web of Science ®Google Scholar
• De Velasco G, Je Y, Bossé D, et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017;5(4):312–318. doi:10.1158/2326-6066.CIR-16-0237
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:10.1200/JCO.2017.77.6385
   PubMed Web of Science ®Google Scholar
• Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant. 2020;20(3):879–883. doi:10.1111/ajt.15617
   PubMed Web of Science ®Google Scholar
• Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol. 2021;66:101386. doi:10.1016/j.trim.2021.101386
   PubMed Web of Science ®Google Scholar
• Kuo FC, Chen CY, Lin NC, Liu C, Hsia CY, Loong CC. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab. Transplant Proc. 2023;55(4):878–883. doi:10.1016/j.transproceed.2023.03.064
   PubMed Web of Science ®Google Scholar